1. Home
  2. APRE vs SINT Comparison

APRE vs SINT Comparison

Compare APRE & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$1.50

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
SINT
Founded
2006
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.1M
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
APRE
SINT
Price
$0.63
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.10
$11.00
AVG Volume (30 Days)
57.0K
23.3K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
59.45
EPS
N/A
N/A
Revenue
N/A
$1,018,000.00
Revenue This Year
N/A
$30.26
Revenue Next Year
N/A
$413.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$1.47
52 Week High
$1.93
$6.78

Technical Indicators

Market Signals
Indicator
APRE
SINT
Relative Strength Index (RSI) 40.85 27.68
Support Level $0.57 N/A
Resistance Level $0.83 $2.98
Average True Range (ATR) 0.06 0.10
MACD -0.01 -0.00
Stochastic Oscillator 34.44 4.56

Price Performance

Historical Comparison
APRE
SINT

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

Share on Social Networks: